Secretion of high amounts of hepatocyte growth factor is a characteristic feature of cancer‐associated fibroblasts with EGFR‐TKI resistance‐promoting phenotype: A study of 18 cases of cancer‐associated fibroblasts
Authors:
- 24 July 2019
- journal article
- research article
- Published by Wiley in Pathology International
- Vol. 69 (8) , 472-480
Abstract
Humoral factors from cancer‐associated fibroblasts (CAFs) reportedly affect epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) resistance in cancer cells with EGFR mutations. The aim of this study was to identify the robust humoral factors secreted from CAFs that induce the primary resistance to EGFR‐TKI. We evaluated the EGFR‐TKI sensitivity of EGFR‐mutant lung adenocarcinoma cell line (PC‐9) treated with condition media (CM) from 18 cases of CAFs and matched non‐cancerous‐tissue‐associated fibroblasts (NCAFs). We measured the expression levels of hepatocyte growth factor (HGF), interleukin‐6, fibroblast growth factor‐2, insulin‐like growth factor‐1, and vascular endothelial growth factor‐A in CAFs and NCAFs. We examined whether HGF neutralizing antibody could annul the EGFR‐TKI resistance induced by CM from CAFs. Compared to CM from NCAFs, CM from CAFs increased the resistance of PC‐9 cells to EGFR‐TKI in five out of 18 cases. Relative expression ratio of HGF messenger RNA was significantly higher in these five CAFs compared to others (P = 0.0013), whereas other cytokines were not. In four of these five cases, the addition of HGF neutralizing antibody significantly decreased the survival ratio of PC‐9 cells. This study suggests that the secretion of higher amounts of HGF is the robust feature of EGFR‐TKI resistance‐promoting CAFs.Keywords
This publication has 29 references indexed in Scilit:
- Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancerCancer Letters, 2013
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 ExpressionPLOS ONE, 2010
- TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancerProceedings of the National Academy of Sciences, 2010
- Fibroblasts associated with cancer cells keep enhanced migration activity after separation from cancer cells: A novel character of tumor educated fibroblastsInternational Journal of Oncology, 2010
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsAnnals of Oncology, 2008